<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629718</url>
  </required_header>
  <id_info>
    <org_study_id>2015-FXY-069</org_study_id>
    <nct_id>NCT02629718</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer</brief_title>
  <acronym>SYSGO-003</acronym>
  <official_title>A Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer(CSEM005)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To clarify the potential benefits of NACT before radical surgery(RS), we perform a phase III,&#xD;
      randomised controlled trial to compare NACT plus RS with RS alone in patients with stages IB2&#xD;
      and IIA2 cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB2 and IIA2&#xD;
      cervical cancer are eligible for our study. They will receive paclitaxel +&#xD;
      cisplatin(TP)/carboplatin(TC) regimen neoadjuvant chemotherapy (NACT) 3 cycles followed by&#xD;
      radical surgery (RS) (type III to V radical hysterectomy plus systematic pelvic&#xD;
      lymphadenectomy) (arm A) or directly radical surgery (arm B). Postoperative pelvic&#xD;
      radiotherapy will be started within 6 weeks after surgery if the patients have pelvic lymph&#xD;
      node metastasis, parametrial involvement, deep stromal invasion or positive margin.&#xD;
      Extended-field external beam therapy, delivering a dose of 4500cGy by a four-field technique,&#xD;
      will be administered to patients with positive para-aortic nodes. High-dose rate&#xD;
      brachytherapy will be delivered to the vaginal stump if patients have positive surgical&#xD;
      margins. The primary end point is 2-years progression-free survival, The secondary end points&#xD;
      is overall survival , rate of response to TP or TC regimen chemotherapy and the quality of&#xD;
      life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>PFS</condition>
  <condition>OS</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>A(NACT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant Chemotherapy followed by Radical Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B(RS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radical Surgery alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NACT (Paclitaxel + Cisplatin or carboplatin)</intervention_name>
    <description>Paclitaxel 150mg/m2 over 3 hours + Cisplatin 70mg/m2 or carboplatin AUC = 6, repeat per 21 days, 3 cycles.</description>
    <arm_group_label>A(NACT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radical surgery</intervention_name>
    <description>Radical hysterectomy (Piver Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling</description>
    <arm_group_label>A(NACT)</arm_group_label>
    <arm_group_label>B(RS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with newly histologically confirmed cervical carcinoma;&#xD;
&#xD;
          -  Histopathology squamaous carcinoma, adenocarcinoma or adeno-squamous carcinoma;&#xD;
&#xD;
          -  Original clinical stage must be IB2 or IIA2 （FIGO);&#xD;
&#xD;
          -  Age between 18-65;&#xD;
&#xD;
          -  Patients must give signed informed consent;&#xD;
&#xD;
          -  P.S status: 0-1;&#xD;
&#xD;
          -  Estimated survival time &gt; 3 months;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of uncontrolled life-threatening illness;&#xD;
&#xD;
          -  Receiving other ways of anti-cancer therapy;&#xD;
&#xD;
          -  Investigator consider the patients can't finish the whole study;&#xD;
&#xD;
          -  With normal liver function test (ALT、AST&gt;2.5×ULN);&#xD;
&#xD;
          -  With normal renal function test (Creatinine&gt;1.5×ULN);&#xD;
&#xD;
          -  WBC&lt;4,000/mm3 or PLT&lt;100,000/mm;&#xD;
&#xD;
          -  Accompany with other malignancy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihong Liu, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jihong Liu, Ph. D</last_name>
    <phone>86-20-87343102</phone>
    <email>Liujih@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ting Wan, Ph. D</last_name>
    <phone>86-20-87343014</phone>
    <email>wanting@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center, Department of Gynecologic Oncology</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting Wan, Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2015</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jihong Liu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>radical surgery</keyword>
  <keyword>cervical carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

